VectorBuilder to Present at the ASHG 2026 Annual Meeting

CHICAGO–(BUSINESS WIRE)–#BioTechNews—VectorBuilder today announced that it will present and exhibit at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montréal, Canada, and that Dr. Morgan Dwyer will present during the meeting.

VB LOGO EN 2
VB LOGO EN 2

Dwyer will present “Development of a Compact Bidirectional Promoter for Coordinated Multi-Gene Expression” as part of the Translational and Technological Advances in Genetic Therapies session on Saturday, October 24 at 8:45 a.m.

The presentation will highlight VectorBuilder’s work developing a compact bidirectional promoter for coordinated multi-gene expression, reflecting the company’s ongoing efforts to develop gene delivery technologies and tools for researchers and therapeutic developers.

Presentation

  • Presenter: Dr Morgan Dwyer, VectorBuilder
  • Title: Development of a Compact Bidirectional Promoter for Coordinated Multi-Gene Expression
  • Session: Translational and Technological Advances in Genetic Therapies
  • Date: Saturday, October 24, 2026
  • Time: 8:45 a.m.

Exhibition

  • Booth: 1103
  • Dates: October 21–23, 2026
  • Hours: 9:30 a.m.–4:30 p.m., with extended hours on Thursday, October 22, until 6:15 p.m.
  • Location: Palais des Congrès de Montréal, Montréal, Canada

Attendees can visit VectorBuilder at Booth 1103 from October 21–23 to learn more about the company’s gene delivery technologies and services. Those interested in connecting with the team can also schedule a meeting during the conference.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Studio allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capabilities, the VectorBuilder team strives to provide effective gene-delivery solutions and develop innovative tools for life sciences research and genetic medicine.

Contacts

Media Contact
[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.